SavedAdd your journal

Journals / Retina-Vitreus / 2019 / Cilt: 28 - Sayı: 1

Diabetic Macular Edema: Evidence based treatment approach

Diabetik Makula Ödeminde Kanıta Dayalı Tedavi Yöntemleri

SİBEL KADAYIFÇILAR
Pages
1–6
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Recently it became possible to attain visual gains with the help of intravitreal corticosteroids and anti-VEGF agents.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Diabetic macular edema is an important cause of visual loss.
📊
Key Findings & Data:Previously the vision could be stabilized with focal/grid laser photocoagulation therapies for central involving macular edema.
💡
Conclusion & Impact:Recently it became possible to attain visual gains with the help of intravitreal corticosteroids and anti-VEGF agents.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Diabetic macular edema is an important cause of visual loss. Previously the vision could be stabilized with focal/grid laser photocoagulation therapies for central involving macular edema. Recently it became possible to attain visual gains with the help of intravitreal corticosteroids and anti-VEGF agents.

Özet

Diyabetik makula ödemi önemli bir görme kaybı nedenidir. Merkezi tutan diyabetik makula ödeminde fokal/grid laser tedavileri ile görmede stabilizasyon sağlanırken son yıllarda intravitreal kortikosteroidler ve anti-VEGF tedaviler ile görme artışları elde etmek mümkün olmuştur.

🔖

Cite This Article

KADAYIFÇILAR, S. (2019). Diabetic Macular Edema: Evidence based treatment approach. Retina-Vitreus, Cilt: 28 - Sayı: 1, 1–6. https://ajindex.com/articles/307862

References (7)

  1. Klein R, Klein BE, Moss SE, et al. The Wisconsin epidemiologic study of diabetic retinopathy. II. Prevalence and risk of diabetic retinopathy when age at diagnosis is less than 30 years. Arch Ophthalmol 1984;102:520-6. Ferris FL 3 rd, Patz A. Macular edema: A complication of diabetic retinopathy. Surv Ophthalmol 1984;28:452-61.
  2. Ding J, Wong TY. Current epidemiology of diabetic retinopathy and diabetic macular edema. Curr Diab Rep 2012;12:346-54. The Diabetes Control and Complications Trial Research Group, Nathan DM, Genuth S, et al. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329:977-86. Writing team for the DCCT/EDIC Research Group, Gubitosi-Klug RA, Sun W, et al. Effects of prior intensive insulin therapy and risk factors on patient-reported visual function outcomes in the Diabetes Control and Complications Trial/ Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Cohort. JAMA Ophthalmol. 2016;134:137-45. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes. BMJ 1998;317:703–13. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood- glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33): Lancet 1998;352:87-53. Early Treatment Diabetic Retinopathy Study Research Group. Photocoagulation for diabetic macular edema. ETDRS report number 1. Arch Ophthalmol 1985;103:1796-806.
  3. Mitchell P, Wong TY, Diabetic Macular Edema Treatment Guideline Working Group. Management paradigms for diabetic macular edema. Am J Ophthalmol 2014;157:505-13.
  4. Nguyen QD, Tatlıpınar S, Shah SM, et al. Vascular endothelial growth factor is a critical stimulus for diabetic macular edema. Am J Ophthalmol 2006;142:961-9.
  5. Sultan MB, Zhou D, Loftus J, et al; for the Macugen 1013 Study Group. A phase 2/3, multicenter, randomized, double-masked, 2-year trial of pegaptanib sodium for the treatment of diabetic macular edema. Ophthalmology 2011;118:1107-18.
  6. Shah SM, Nguyen QD, Tatlıpınar S, et al. One-year results of the READ study: ranibizumab for edema of the macula in diabetes. Retina Soc Ann Meet, Cape Town 2006.
  7. Massin P, Bandello F, Garweg JG, et al. Safety and effi cacy of ranibizumab in diabetic macular edema (RESOLVE Study): a 12-month, randomized, controlled